No connection

Search Results

LGND vs NVST

LGND
Ligand Pharmaceuticals Incorporated
NEUTRAL
Price
$204.92
Market Cap
$4.09B
Sector
Healthcare
AI Confidence
85%
NVST
Envista Holdings Corporation
NEUTRAL
Price
$25.94
Market Cap
$4.23B
Sector
Healthcare
AI Confidence
80%

Valuation

P/E Ratio
LGND
33.43
NVST
92.64
Forward P/E
LGND
20.7
NVST
16.64
P/B Ratio
LGND
3.98
NVST
1.37
P/S Ratio
LGND
15.24
NVST
1.55
EV/EBITDA
LGND
46.98
NVST
12.83

Profitability

Gross Margin
LGND
64.29%
NVST
55.02%
Operating Margin
LGND
33.59%
NVST
10.74%
Profit Margin
LGND
46.42%
NVST
1.73%
ROE
LGND
13.47%
NVST
1.56%
ROA
LGND
2.36%
NVST
2.78%

Growth

Revenue Growth
LGND
39.4%
NVST
15.0%
Earnings Growth
LGND
--
NVST
3146.1%

Financial Health

Debt/Equity
LGND
0.44
NVST
0.51
Current Ratio
LGND
22.23
NVST
2.38
Quick Ratio
LGND
21.83
NVST
1.93

Dividends

Dividend Yield
LGND
--
NVST
--
Payout Ratio
LGND
0.0%
NVST
0.0%

AI Verdict

LGND NEUTRAL

LGND presents a dichotomy between exceptional operational profitability and poor deterministic health/value scores. While the company boasts a massive 46.42% profit margin and strong revenue growth (39.4%), the Piotroski F-Score of 3/9 indicates weak financial trend momentum. The stock is trading at a significant premium to its Graham Number ($84.23) and Intrinsic Value ($42.91), suggesting the market is pricing in aggressive future growth. Bearish insider activity and a weak technical trend further temper the outlook despite strong analyst target prices.

Strengths
Exceptional profit margins (46.42%) and gross margins (64.29%)
Strong top-line growth with 39.40% YoY revenue increase
Extremely high liquidity indicated by a Current Ratio of 22.23
Risks
Severe overvaluation relative to Graham and Intrinsic value benchmarks
Weak financial health trend as evidenced by a Piotroski F-Score of 3/9
Bearish insider sentiment with 9 sell transactions and 0 buys
NVST NEUTRAL

NVST presents a complex profile with a stable Piotroski F-Score of 4/9 and a significant valuation gap, as the current price of $25.94 far exceeds the Graham Number ($10.93) and Intrinsic Value ($8.26). While the company shows strong short-term price momentum (+61.3% 1Y) and a highly attractive Forward P/E of 16.64, its trailing P/E of 92.64 and razor-thin profit margin of 1.73% indicate a precarious transition period. The bullish analyst consensus is countered by bearish insider sentiment and a 0/100 technical trend, suggesting the market is pricing in a recovery that has not yet fully materialized in the fundamentals.

Strengths
Strong liquidity with a Current Ratio of 2.38 and Quick Ratio of 1.93
Healthy Gross Margin of 55.02% indicating strong product pricing power
Manageable leverage with a Debt/Equity ratio of 0.51
Risks
Severe overvaluation relative to defensive metrics (Graham Number $10.93)
Extremely low net profit margin (1.73%) leaving little room for error
Bearish insider activity and technical trends

Compare Another Pair

LGND vs NVST: Head-to-Head Comparison

This page compares Ligand Pharmaceuticals Incorporated (LGND) and Envista Holdings Corporation (NVST) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.

Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.

Home
Terminal
AI Chat
Markets
Profile